MannKind Corporation has acquired scPharmaceuticals for an undisclosed amount. This corporate acquisition brings together two pharmaceutical companies with distinct yet complementary focuses in drug delivery and patient care. The transaction signifies a strategic expansion for MannKind into new therapeutic areas and delivery methods.
scPharmaceuticals is a clinical-stage pharmaceutical company specializing in developing and commercializing products designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery. Its proprietary platform aims to transform infused therapies, advance patient care, and reduce healthcare costs, particularly in cardiorenal solutions. A key product is FUROSCIX, an innovative treatment for edema due to chronic heart failure and chronic kidney disease. MannKind Corporation is a patient-centric leader, active in cardiometabolic and lung diseases.
The acquisition is strategically designed to leverage scPharmaceuticals’ innovative platform and product portfolio within MannKind’s established operational framework. Synergies are expected from integrating scPharmaceuticals’ expertise in pharmaceutical development, drug-device combinations, and product commercialization, especially in its cardiorenal focus, with MannKind’s existing operations. This move is anticipated to diversify and accelerate MannKind’s revenue growth by adding a commercial product that addresses significant unmet patient needs through patient-centric approaches.
The combined entity is positioned to enhance its footprint in the pharmaceutical landscape, offering a broader range of solutions that improve patient quality of life and reduce healthcare burden. This acquisition underscores a commitment to advancing integrated, value-driven care and expanding access to critical therapies, particularly in managing chronic conditions.